# OnCo record nct07387926 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07387926/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07387926", "NCT07387926" ;
  schema:name "Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)"@en ;
  schema:description "A phase 1/2 trial of Asciminib, Dexamethasone, Vincristine, Blinatumomab, Methotrexate and Cytarabine in acute lymphoblastic leukaemia, run by Novartis Pharmaceuticals, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07387926/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07387926> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2026-07-05" ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/all-paediatric-relapsed/>, <https://onco.cc/cancers/all-ph-like/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/asciminib/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/cytarabine/> ;
  onco:companies <https://onco.cc/companies/novartis/> .